Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00934544 · OUTCOME

Duration of Follow-up by Treatment

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial · Source last updated 2019-08-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
participants
Interval / dispersion
Not reported
Time frame
baseline, 260 weeks (end of study)

What was measured

Number of Participants with duration of Follow up

Analysis population: Safety Set Numbers of Participants Analyzed reflect only those participants who were randomized to either Ruxolitinib or Best Available Therapy and do not count those participants who could have crossed over to Ruxolitinib

Groups in this outcome

Ruxolitinib

5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule

Best Available Therapy (BAT)

Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Ruxolitinib146
Best Available Therapy (BAT)73

Reported measurements

<=1 year
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib16Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)15Not reportedNot reportedNot reportedNot reported
>1 year - <=2 years
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib21Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)10Not reportedNot reportedNot reportedNot reported
>2 years - <=3 years
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib9Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)13Not reportedNot reportedNot reportedNot reported
>3 years - <=4 years
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib12Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)5Not reportedNot reportedNot reportedNot reported
>4 years - <=5 years
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib27Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)8Not reportedNot reportedNot reportedNot reported
5 years
Values in participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Ruxolitinib61Not reportedNot reportedNot reportedNot reported
Best Available Therapy (BAT)22Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        16
      2. group Id
        OG001
        value
        15
    title
    <=1 year
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        21
      2. group Id
        OG001
        value
        10
    title
    >1 year - <=2 years
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        9
      2. group Id
        OG001
        value
        13
    title
    >2 years - <=3 years
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        12
      2. group Id
        OG001
        value
        5
    title
    >3 years - <=4 years
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        27
      2. group Id
        OG001
        value
        8
    title
    >4 years - <=5 years
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        61
      2. group Id
        OG001
        value
        22
    title
    5 years
denoms
  1. counts
    1. group Id
      OG000
      value
      146
    2. group Id
      OG001
      value
      73
    units
    Participants
description
Number of Participants with duration of Follow up
groups
  1. description
    5 milligram tablets administered orally in an outpatient setting according to the protocol-specified dosing schedule
    id
    OG000
    title
    Ruxolitinib
  2. description
    Commercially available therapy, oral or parenteral, per manufacturer's instructions and Investigator discretion. BAT included the option of no treatment.
    id
    OG001
    title
    Best Available Therapy (BAT)
param Type
NUMBER
population Description
Safety Set Numbers of Participants Analyzed reflect only those participants who were randomized to either Ruxolitinib or Best Available Therapy and do not count those participants who could have crossed over to Ruxolitinib
reporting Status
POSTED
time Frame
baseline, 260 weeks (end of study)
title
Duration of Follow-up by Treatment
type
SECONDARY
unit Of Measure
participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice